Everything below concerns 瑞他鲁肽. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-09-12. Numbers and descriptions here follow the published literature rather than marketing material.
Mechanistic proposals link each receptor to a different physiological role. Activation of the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors is associated with reduced appetite, slower gastric emptying, and glucose-dependent insulin release. Glucagon receptor signaling, by contrast, is associated with increased energy expenditure and altered lipid handling, though it can also raise blood glucose. The design intent is to balance these contributions so that weight reduction is enhanced without unacceptable glycemic trade-offs. How well that balance holds across individuals is not fully resolved.
Published information places retatrutide in clinical development rather than on the market as an approved therapy. Early-stage and mid-stage trials have examined tolerability and changes in body weight, and larger studies continue to report results over time. Open questions include the durability of effects after treatment stops, the composition of weight lost, and cardiovascular outcomes over long periods. Statements about definitive benefit should therefore be treated as provisional. Regulatory status varies by jurisdiction and changes as applications are reviewed.
Retatrutide is an investigational synthetic peptide designed to activate three distinct receptor systems within a single molecule. Its pharmacological profile combines activity at the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This arrangement places it within a broader class of agents often described as multi-agonists, which contrast with compounds that engage one or two targets. Research interest centers on whether simultaneous signaling produces effects that single-receptor agonists cannot achieve alone. A single molecular entity also simplifies manufacturing and delivery logistics compared with combining separate agents.
化学修饰延长了分子在体内的停留时间，使较低频次的给药安排成为可能。脂肪酸侧链通过与白蛋白结合延缓清除，非天然氨基酸则降低酶解速率。这些修饰同时改变分子的溶解性与稳定性，需要在制剂设计和储存条件中一并考虑。修饰引入的免疫原性风险也属于开发过程中需要评估的项目。
该化合物处于临床试验阶段，尚未在多数地区取得上市许可。公开信息主要来自企业公告、学术会议摘要与试验注册平台记录，完整数据仍在逐步披露。关于长期疗效与安全性的判断，需要等待规模更大、随访更久的研究结果，目前不宜对最终结论作出预判。
retatrutide 是一种人工合成的多肽，设计目标是同时作用于 GIP、GLP-1 与胰高血糖素三种受体。这种三重激动设计试图把多条代谢通路的调节整合进单一分子，而不是只依赖一种肠促胰素受体。分子骨架以天然肽序列为基础，经过非天然氨基酸替换和脂肪酸侧链修饰，以获得更长的作用时间。该方向属于多受体激动剂研究的一部分，与双重激动剂的工作并行推进。
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Studied for metabolic indications |
| Receptor activity | GIP, GLP-1, and glucagon | Single molecule, three targets |
| Development status | Investigational | Not an approved therapy |
| Common synonym | LY3437943 | Development designation |
| Administration route | Subcutaneous injection | As used in clinical studies |
Retatrutide is an investigational synthetic peptide that acts on three receptor targets at once: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. It is developed by Eli Lilly and appears in the literature and in trial registries under the code LY3437943. The molecule belongs to a class of engineered peptides designed to resist rapid breakdown and permit infrequent subcutaneous administration. No regulatory agency has approved it for clinical use, and all available human data come from controlled trials rather than from routine practice.
The intended pharmacology combines three signals in one molecule. GLP-1 receptor activation reduces appetite and slows gastric emptying, effects already exploited by approved incretin-based therapies. GIP receptor engagement is associated with improved insulin sensitivity and with direct effects on adipose tissue, although how much it contributes to overall outcomes is still debated. Glucagon receptor agonism raises energy expenditure and supports hepatic lipid handling, a mechanism that also tends to increase glucose output. The triple profile is hypothesized to produce a larger metabolic effect than single or dual agonism, but the relative weight of each receptor in humans is not settled.
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
Body composition is assessed with dual-energy X-ray absorptiometry or comparable methods, which separate fat mass from lean mass. Reported losses include both compartments, and the ratio between them is a subject of ongoing analysis rather than a settled result. Waist circumference, blood pressure, and lipid panels are collected as supporting measures. Resting energy expenditure and substrate oxidation are measured in smaller mechanistic studies, where glucagon receptor activity is expected to matter. These substudies are typically short and small, so their findings carry wide uncertainty.
Interpretation depends on study phase and duration. Phase 2 programs are powered for weight and safety signals, not for cardiovascular or renal outcomes, which require event-driven designs. Gastrointestinal events such as nausea, diarrhea, vomiting, and constipation are the most frequently reported adverse effects and tend to cluster around dose escalation. Small increases in heart rate have been described. Because follow-up after treatment discontinuation is limited, questions about weight regain and durability are open rather than answered.
瑞他鲁肽是一种在研合成肽，同时作用于胰高血糖素样肽-1、葡萄糖依赖性促胰岛素多肽和胰高血糖素受体。该分子属于多受体激动剂类别，尚未获得任何监管机构的上市批准。当前临床开发主要针对肥胖和2型糖尿病，研究代号为LY3437943。已确立的信息包括受体靶点和部分中期试验结果；最终疗效、长期安全性和适用人群仍属开放问题。
开发进程从早期单次和多次给药研究推进至大规模后期试验。公开报告显示，参与者在体重和相关代谢指标上出现变化，但完整数据需经同行评审并接受独立复核。试验设计通常包括随机、双盲和对照设置，以区分药物效应与行为干预。监管提交和标签范围尚未确定；长期维持效果与心血管结局仍是开放问题。
与仅靶向单一受体的同类药物相比，瑞他鲁肽增加胰高血糖素受体成分，理论上可提高能量消耗并改变脂肪分布。临床中观察到的体重变化是否主要来自该额外机制，目前尚无定论。胃肠道反应是该类药物常见不良事件，试验中通过剂量递增和监测进行管理。停药后体重反弹、个体差异和长期耐受性仍需更多数据。
Kissinger went to Paris on 3 May to meet Tho with orders from Nixon that North Vietnam must "settle or else!" Nixon complained that Kissinger was "obsessed" with the need for a peace treaty while he charged that he now wished he followed his instincts to bomb North Vietnam in 1970, saying if he had done so, the war would have been over by now. On 2 May 1972, the PAVN had captured Quang Tri, an important provincial city in South Vietnam, and as a result of this victory, Tho was in no mood for a compromise. Though Kissinger in general shared Nixon's determination to be tough, he was afraid that the president would overreact and destroy the budding détente with the Soviet Union and China by striking too hard at North Vietnam. Moreover, after the rupture caused by the Cambodian incursion, Kissinger was trying hard to rebuild his relations with the liberal American intelligentsia, saying he did want to become "this administration's Walt Rostow". Kissinger's predecessor, Rostow, was once a professor at Harvard, Oxford, MIT and Cambridge, but by serving as the National Security Advisor, he had been shunned by the Ivy League universities and ended up at the lowly University of Texas, a fate that Kissinger was determined to avoid. On 5 May 1972, Nixon ordered the U.S. Air Force to start bombing Hanoi and Haiphong and on 8 May ordered the U.S. Navy to mine the coast of North Vietnam.
perform both visual and digital oral health examinations. prescribe oral prosthetics to dental technicians. prescribe radiography. Supervise auxiliary personnel in the performance of their delegated duties. Create impressions of peoples' teeth, in order to make customized partial or complete dentures and mouthguards. Refer patients with more complex issues to a dentist or specialist dentist when appropriate. Treat bruxism and sleep apnea by using night guard and anti snoring device. Treat teeth whitening by using custom bleach tray. Maintain and repair existing dental prostheses. Educate patients on oral health hygiene techniques.
Chemical synthesis (chemical combination) is the artificial execution of chemical reactions to obtain one or more products. This occurs by physical and chemical manipulations, usually involving one or more reactions. In modern laboratory uses, the process is reproducible and reliable. A chemical synthesis involves one or more compounds (known as reagents or reactants) that will experience a transformation under certain conditions. Various reaction types can be applied to formulate a desired product. Many reactions require some form of processing ("work-up") or purification procedure to isolate the final product. The amount produced by chemical synthesis is known as the reaction yield. Typically, yields are expressed as a mass in grams (in a laboratory setting) or as a percentage of the total theoretical quantity that could be produced based on the limiting reagent. A side reaction is an unwanted chemical reaction that can reduce the desired yield. The word synthesis was used first in a chemical context by the chemist Hermann Kolbe.
Sources: en.wikipedia.org
=== Recurring === Dave Franco as Danny Wegbriet, Yoshi's shifty, stoner, childhood friend, who usually ends up making things worse when Yoshi turns to him for help. He notably wears some sort of new hat in each of his appearances. Michaela Dietz as Hannah Schwooper, Avi and Jen's daughter. Born in 2009, she is technically not Jewish as her mother is not and Avi did not raise her around the culture due to his own disassociation from religion. In middle school Hannah has a good relationship with her father and shares his interests but is isolated from children her own age, though she does find a friend group at the end of "Wolves". She is passionate about photography, and also has a strained relationship with Jen after her and her father divorce. She grows more interested in her Jewish heritage adound this time as well, though fears she is not "Jewish enough" to do so. Gina Rodriguez as Rachel "Baby" Feldstein, Shira's bisexual childhood best friend. The two began secretly hooking up during their senior year of high school, with Shira genuinely having feelings for but Baby acting dodgey about having a conversation about their relationship. In 2002, Shira sneaks out of her mom’s ceremony to prom to make things official but she catches Rachel kissing a boy. During their ensuring argument she discovers Rachel never saw their relationship as anything more than a mindless fling, and a heartbroken Shira angrily ends their relationship, though Rachel callously retorted back they never had anything, further devastating Shira.
== Honors and recognition == Knudsen received the 2023 Paul Langerhans Medal by the German Diabetes Society for her work developing liraglutide. In October 2023, she received the STAT Biomedical Innovation award, and in 2024, she received the Mani L. Bhaumik Breakthrough of the Year Award. In 2024 she received the Lasker Award in clinical research. In 2024, Knudsen received the Golden Plate Award of the American Academy of Achievement, presented by Awards Council member Robert S. Langer. In 2025, Knudsen received the 2025 Breakthrough Prize in Life Sciences.
== Applications == Poisonous compounds may be useful either for their toxicity, or, more often, because of another chemical property, such as specific chemical reactivity. Poisons are widely used in industry and agriculture, as chemical reagents, solvents or complexing reagents, e.g. carbon monoxide, methanol and sodium cyanide, respectively. They are less common in household use, with occasional exceptions such as ammonia and methanol. For instance, phosgene is a highly reactive nucleophile acceptor, which makes it an excellent reagent for polymerizing diols and diamines to produce polycarbonate and polyurethane plastics. For this use, millions of tons are produced annually. However, the same reactivity makes it also highly reactive towards proteins in human tissue and thus highly toxic. In fact, phosgene has been used as a chemical weapon. It can be contrasted with mustard gas, which has only been produced for chemical weapons uses, as it has no particular industrial use. Biocides need not be poisonous to humans, because they can target metabolic pathways absent in humans, leaving only incidental toxicity. For instance, the herbicide 2,4-dichlorophenoxyacetic acid is a mimic of a plant growth hormone, which causes uncontrollable growth leading to the death of the plant. Humans and animals, lacking this hormone and its receptor, are unaffected by this, and need to ingest relatively large doses before any toxicity appears. Human toxicity is, however, hard to avoid with pesticides targeting mammals, such as rodenticides.
Sources: en.wikipedia.org
It is described as a single molecule that acts at three receptors: the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This triple activity distinguishes it from agents that target one or two of these pathways.
It is characterized in the literature as an investigational agent under clinical study. Approval status depends on jurisdiction, and readers should check current regulatory information rather than assume availability.
The combination is intended to pair appetite-related and glucose-related effects with mechanisms that increase energy expenditure. Whether the combined profile offers advantages over simpler agonists is the subject of ongoing research.
指同一个分子能激活 GIP、GLP-1 和胰高血糖素三类受体。它与只激活一到两种受体的同类分子在设计思路上有所区别。这种设计的目的在于覆盖更多代谢调节通路。